The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis
Article first published online: 14 JAN 2014
Copyright © 2013 John Wiley & Sons, Ltd.
Diabetes/Metabolism Research and Reviews
Volume 30, Issue 1, pages 11–22, January 2014
How to Cite
Schopman, J. E., Simon, A. C. R., Hoefnagel, S. J. M., Hoekstra, J. B. L., Scholten, R. J. P. M. and Holleman, F. (2014), The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab. Res. Rev., 30: 11–22. doi: 10.1002/dmrr.2470
- Issue published online: 14 JAN 2014
- Article first published online: 14 JAN 2014
- Accepted manuscript online: 12 SEP 2013 06:21AM EST
- Manuscript Accepted: 9 SEP 2013
- Manuscript Revised: 7 SEP 2013
- Manuscript Received: 21 APR 2013
- 1National Institute for Health and Clinical Excellence. CG87 type 2 diabetes – newer agents (a partial update of CG66): short guideline, 2011.
- 2International Diabetes Federation. Global guideline for type 2 diabetes, 2012.
- 6Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011; 13(2): 160–168., , , et al.
- 7Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63(9): 1395–1406., , , , , .
- 11A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010; 27(3): 318–326., .
- 14Liraglutide: a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13(4): 348–356., , , , , .
- 17Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9(5): 733–745., , , , , .
- 18Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab 2010; 12(4): 341–347., , , .
- 20Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27(6): 1335–1342., , , , .
- 21Liraglutide: a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26(3): 268–278., , , et al.
- 27Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab 2011; 13(1): 81–88., , , et al.